{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:13:11Z","timestamp":1794892391151,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-026-01376-1","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:14:22Z","timestamp":1769019262000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Beyond discovery: are we understanding PET tracers as fast as we invent them? a critical review"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4694-5850","authenticated-orcid":false,"given":"Efrah Ahmed","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"2","key":"1376_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging\u2014version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1376_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1148\/radiographics.19.1.g99ja0761","volume":"19","author":"PD Shreve","year":"1999","unstructured":"Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19(1):61\u201377. https:\/\/doi.org\/10.1148\/radiographics.19.1.g99ja0761.","journal-title":"Radiographics"},{"issue":"5","key":"1376_CR3","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1148\/rg.2019180093","volume":"39","author":"MS Clark","year":"2019","unstructured":"Clark MS, Packard AT, Johnson DR, Johnson GB. Pitfalls of a mixed metabolic response at PET\/CT. Radiographics. 2019;39(5):1461\u201375. https:\/\/doi.org\/10.1148\/rg.2019180093.","journal-title":"Radiographics"},{"issue":"5","key":"1376_CR4","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466\u201386. https:\/\/doi.org\/10.1007\/s00259-022-06089-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1376_CR5","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.euo.2022.05.003","volume":"5","author":"S Fanti","year":"2022","unstructured":"Fanti S, Briganti A, Emmett L, Giammarile F, Bomanji J, Ceci F, et al. EAU\u2013EANM consensus statements on the role of PSMA PET\/CT in patients with prostate cancer and with respect to [177Lu]Lu-PSMA radioligand therapy. Eur Urol Oncol. 2022;5(5):530\u20136. https:\/\/doi.org\/10.1016\/j.euo.2022.05.003.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"1376_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2967\/jnumed.119.229187","volume":"61","author":"I Rauscher","year":"2020","unstructured":"Rauscher I, Kr\u00f6nke M, K\u00f6nig M, Gafita A, Maurer T, Horn T, et al. Matched-pair comparison of 68Ga-PSMA-11 PET\/CT and 18F-PSMA-1007 PET\/CT: frequency of non-specific findings and pitfalls. J Nucl Med. 2020;61(1):51\u20137. https:\/\/doi.org\/10.2967\/jnumed.119.229187.","journal-title":"J Nucl Med"},{"issue":"12","key":"1376_CR7","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1007\/s00259-021-05424-x","volume":"48","author":"H Gr\u00fcnig","year":"2021","unstructured":"Gr\u00fcnig H, Maurer A, Thali Y, Fanti S, Weber WA, Eiber M, et al. Focal unspecific bone uptake on [18F]-PSMA-1007 PET: frequency and impact on clinical management. Eur J Nucl Med Mol Imaging. 2021;48(12):4403\u201313. https:\/\/doi.org\/10.1007\/s00259-021-05424-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1376_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41391-023-00755-2","volume":"27","author":"S Huang","year":"2024","unstructured":"Huang S, Yang S, He J, Zhao H, Fu Z, Yang W, et al. Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11: a systematic review. Prostate Cancer Prostatic Dis. 2024;27(2):195\u2013205. https:\/\/doi.org\/10.1038\/s41391-023-00755-2.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1376_CR9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.186767","author":"M Eiber","year":"2017","unstructured":"Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, et al. Prostatespecific membrane antigen ligands for imaging and therapy. J Nucl Med. 2017. https:\/\/doi.org\/10.2967\/jnumed.116.186767.","journal-title":"J Nucl Med"},{"issue":"6","key":"1376_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. 68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801\u20135. https:\/\/doi.org\/10.2967\/jnumed.119.227967.","journal-title":"J Nucl Med"},{"issue":"3","key":"1376_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. 68Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTAcontaining FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60(3):386\u201392. https:\/\/doi.org\/10.2967\/jnumed.118.215913.","journal-title":"J Nucl Med"},{"issue":"9","key":"1376_CR12","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415\u201322. https:\/\/doi.org\/10.2967\/jnumed.118.210443.","journal-title":"J Nucl Med"},{"issue":"12","key":"1376_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"issue":"3","key":"1376_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00259-0173853-7","volume":"45","author":"A Kaalep","year":"2018","unstructured":"Kaalep A, Sera T, Oyen W, Krause BJ, Chiti A, Liu Y, et al. EANM\/EARL FDGPET\/CT accreditation - summary results from the first 200 accredited imaging systems. Eur J Nucl Med Mol Imaging. 2018;45(3):412\u201322. https:\/\/doi.org\/10.1007\/s00259-0173853-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1376_CR15","unstructured":"IMV 2024 PET market summary report. AuntMinnie.com. 2024. https:\/\/www.auntminnie.com\/clinical-news\/molecular-imaging\/article\/15665651\/pet-scan-volumes-continue-to-grow"},{"issue":"6","key":"1376_CR16","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096.","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5(6):856\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096.","journal-title":"JAMA Oncol"},{"issue":"12","key":"1376_CR17","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.7150\/thno.11814","volume":"13","author":"BJ Burkett","year":"2023","unstructured":"Burkett BJ, Kiess AP, Bauman G, Liu H, Valliant JF, Reilly RM, et al. A review of theranostics: perspectives on emerging radiopharmaceuticals and clinical translation. Theranostics. 2023;13(12):3552\u201390. https:\/\/doi.org\/10.7150\/thno.11814.","journal-title":"Theranostics"},{"issue":"8","key":"1376_CR18","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00259-022-05780-2","volume":"49","author":"E Lopci","year":"2022","unstructured":"Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, et al. Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [18F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging. 2022;49(8):2323\u201341. https:\/\/doi.org\/10.1007\/s00259-022-05780-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"1376_CR19","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2967\/jnumed.120.242560","volume":"61","author":"C Meyer","year":"2020","unstructured":"Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, et al. Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 2020;61(8):1171\u20137. https:\/\/doi.org\/10.2967\/jnumed.120.242560.","journal-title":"J Nucl Med"},{"issue":"Suppl 2","key":"1376_CR20","doi-asserted-by":"publisher","first-page":"s5","DOI":"10.2967\/jnumed.124.268756","volume":"66","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. J Nucl Med. 2025;66(Suppl 2):s5\u201317. https:\/\/doi.org\/10.2967\/jnumed.124.268756.","journal-title":"J Nucl Med"},{"issue":"13","key":"1376_CR21","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","volume":"48","author":"FL Giesel","year":"2021","unstructured":"Giesel FL, Kratochwil C, Schlittenhardt J, Dendl K, Eiber M, Staudinger F, et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET\/CT in cancer patients. Eur J Nucl Med Mol Imaging. 2021;48(13):4377\u201385. https:\/\/doi.org\/10.1007\/s00259-021-05307-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1376_CR22","doi-asserted-by":"publisher","DOI":"10.34172\/ijhpm.8664","volume":"13","author":"N Freudenberg","year":"2024","unstructured":"Freudenberg N. Title. Int J Health Policy Manag. 2024;13:8664. https:\/\/doi.org\/10.34172\/ijhpm.8664.","journal-title":"Int J Health Policy Manag"},{"key":"1376_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-023-00230-2","volume":"9","author":"A Korde","year":"2024","unstructured":"Korde A, Patt M, Selivanova SV, et al. Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework. EJNMMI Radiopharm Chem. 2024;9:2. https:\/\/doi.org\/10.1186\/s41181-023-00230-2.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"1376_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/RLU.0000000000003742","volume":"47","author":"A Alavi","year":"2022","unstructured":"Alavi A, Werner TJ, H\u00f8ilund-Carlsen PF, Langen KJ, Revheim ME, Sadeghi R. Potential and most relevant applications of total-body PET. Clin Nucl Med. 2022;47(1):57\u201363. https:\/\/doi.org\/10.1097\/RLU.0000000000003742.","journal-title":"Clin Nucl Med"},{"key":"1376_CR25","doi-asserted-by":"publisher","first-page":"422","DOI":"10.2967\/jnumed.120.247197","volume":"62","author":"CS Cutler","year":"2021","unstructured":"Cutler CS, Bailey E, Kumar V, Schwarz SW, Bom HS, Hatazawa J, et al. Title. J Nucl Med. 2021;62:422\u201330. https:\/\/doi.org\/10.2967\/jnumed.120.247197.","journal-title":"J Nucl Med"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01376-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01376-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01376-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:20:41Z","timestamp":1770985241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01376-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1376"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01376-1","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This is a review article based on published literature and does not involve human subjects\u2019 research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares no competing interests. No financial support or other relationships exist that could be perceived as influencing the objectivity of this review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}